huDMPK/huTFRC Mouse
제품명
huDMPK/huTFRC Mouse
제품 ID
C002012
품종 계통
C57BL/6NCya-Dmpktm1(hDMPK)Tfrctm2(hTFRC)/Cya
Backgroud
C57BL/6NCya
상태
이 마우스 계통을 논문에서 사용할 경우, “huDMPK/huTFRC Mouse (카탈로그 번호 C002012)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
유전자 별칭
DM, DM1, DMK, MDPK, DM1PK, MT-PK, T9, TR, TFR, p90, CD71, TFR1, TRFR, IMD46
염색체
Chr 19, Chr 3
Datasheet
품종 계통 설명
Myotonic dystrophy type 1 (DM1) is a multi-system rare disease, with the DMPK gene serving as its pathogenic target. Patients exhibit highly diverse clinical manifestations across multiple systems, primarily including peripheral skeletal muscle atrophy, myocardial conduction abnormalities, insulin resistance, as well as central nervous system (CNS) complications (such as cognitive impairment and hypersomnia) [1]. Transferrin receptor 1 (TFRC) features a distinct expression and tissue distribution profile in vivo, serving as a critical receptor vehicle for the peripheral and central targeted delivery of current nucleic acid therapeutics. In the peripheral system, TFRC is highly expressed on the surface of skeletal muscle and myocardial cells, and has been successfully utilized to develop antibody-oligonucleotide conjugates (e.g., AOC 1001) designed for targeted DMPK silencing in muscles; in the central nervous system, TFRC is expressed on brain capillary endothelial cells, making it a core target for studying receptor-mediated transcytosis (RMT) across the blood-brain barrier (BBB).
The huDMPK/huTFRC mouse is a dual-gene humanized model obtained by crossing the huDMPK mouse (Catalog No.: C001882) with the huTFRC mouse (Catalog No.: C001860). This model can be utilized for the screening, pharmacodynamic evaluation, safety assessment, and mechanism-of-action studies of dual-target therapeutics against DMPK/TFRC, as well as comprehensive research on myotonic dystrophy type 1 (DM1) and its associated complications, including muscle atrophy, cardiac conduction abnormalities, insulin resistance, and central nervous system pathology.
Reference
Liu J, Guo ZN, Yan XL, Yang Y, Huang S. Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1. Front Aging Neurosci. 2021 Nov 15;13:755392.
변형 전략
The huDMPK/huTFRC mouse is a dual-gene humanized model obtained by crossing the huDMPK mouse (Catalog No.: C001882) with the huTFRC mouse (Catalog No.: C001860).
Figure 1. Diagram of the gene editing strategy for the generation of huDMPK mice. The sequences upstream of exon 1 to intron 10 of the mouse Dmpk gene were replaced with the sequences from upstream of exon 1 to downstream of the human DMPK gene.
Figure 2. Gene editing strategy of huTFRC mice. The mouse Tfrc endogenous extracellular domain was replaced with the human TFRC extracellular domain. The murine cytoplasmic and helical regions were kept.
응용 분야
Screening, pharmacodynamic evaluation, safety assessment, and mechanism-of-action studies of dual-target therapeutics against DMPK/TFRC;
Comprehensive research on myotonic dystrophy type 1 (DM1) and its associated complications, including muscle atrophy, cardiac conduction abnormalities, insulin resistance, and central nervous system pathology.
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.